Welcome to our dedicated page for Ernexa news (Ticker: ERNA), a resource for investors and traders seeking the latest updates and insights on Ernexa stock.
Eterna Therapeutics Inc (ERNA) is a pioneering biopharmaceutical company developing off-the-shelf cell therapies using advanced mRNA engineering and iPSC platforms. This page provides investors and researchers with centralized access to official announcements, clinical progress updates, and strategic developments related to the company’s innovative approach to treating solid tumors and complex diseases.
Discover timely updates on ERNA-101’s preclinical advancements, partnership milestones with industry leaders like Factor Bioscience, and regulatory filings. Our curated news collection simplifies tracking of key initiatives in cytokine delivery systems, allogeneic cell therapies, and targeted oncology solutions – critical areas for stakeholders monitoring next-generation immunotherapy platforms.
All content is sourced directly from company releases to ensure accuracy and compliance. Bookmark this page for efficient monitoring of Eterna’s progress in transforming cancer treatment through engineered mesenchymal stem cells and tumor microenvironment modulation technologies.
Ernexa Therapeutics (Nasdaq: ERNA) presented preclinical data at the American Society of Hematology Annual Meeting on Dec 8, 2025 showing its lead candidate ERNA-101 (iPSC-derived MSCs) reprogrammed immunosuppressive tumor microenvironments into pro-inflammatory states.
The study reported IL-7/IL-15-secreting iMSCs produced supraphysiologic cytokine levels ~20-fold higher than prior engineered T-cell approaches, drove robust T-cell expansion, sustained STAT5 signaling, macrophage polarization to a pro-inflammatory phenotype, and prolonged survival in an immunocompetent ovarian cancer model. The company said ERNA-101 supports an off-the-shelf, scalable approach and plans first-in-human trials next year.
Ernexa Therapeutics (Nasdaq: ERNA) will present preclinical data from its iPSC-derived iMSC platform in an oral presentation at the 67th ASH Annual Meeting in Orlando, Dec 6-9, 2025. The talk, titled "Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments into distinct Pro-inflammatory TMEs," (abs25-15026) is scheduled for Dec 6, 2025, 3:00–3:15 PM EST in Chapin Theater (320).
The presentation covers preclinical findings supporting ERNA-101, Ernexa's lead ovarian cancer candidate and its approach to reprogram TMEs to stimulate T-cell anti-tumor activity.
Ernexa Therapeutics (Nasdaq: ERNA) appointed Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board on December 2, 2025. Dr. Winer is a gynecologic oncologist and translational scientist who serves as Professor (Clinician Educator) at Wayne State University School of Medicine and practices at Barbara Ann Karmanos Cancer Institute.
The appointment strengthens clinical and translational expertise as Ernexa advances its iMSC cell therapy platform and lead program ERNA-101 toward first-in-human trials, with a focus on ovarian cancer and expansion into inflammatory and autoimmune indications.
Ernexa Therapeutics (Nasdaq: ERNA) will present at Oxford Global's Cell 2025 in London on November 11–12, 2025. Sanjeev Luther, President and CEO, will give an oral talk titled "Preparing Cell Therapies for Clinics" on Nov 12 at 12:50 PM GMT and join a panel on Nov 12 at 4:35 PM GMT addressing development, funding, and regulatory strategies for its engineered induced mesenchymal stem cell (iMSC) platform. Presentations focus on trial design, early regulatory engagement, partnerships, and scalable design to translate cell therapies into clinical practice.
Ernexa Therapeutics (Nasdaq: ERNA) reported continued operational progress and preclinical advancement on Nov 10, 2025. The company said its operating loss declined 44% year-over-year for the nine months ended Sept 30, 2025, and highlighted a partnership with Cellipont Bioservices to advance lead program ERNA-101 toward clinical trials.
Key program milestones disclosed include a 58.2% preclinical survival advantage for ERNA-101, planned completion of IND-enabling studies and an IND submission by Q1 2026, and a targeted first-in-human Phase 1 start in H2 2026. ERNA-201 remains in preclinical development with a pre-IND meeting anticipated by Q1 2026.
Ernexa Therapeutics (Nasdaq: ERNA) participated in a Virtual Investor “What This Means” segment on Nov. 6, 2025 to discuss a recently announced partnership with Cellipont Bioservices.
The agreement covers Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for ovarian cancer, into clinical manufacturing and clinical trials. President and CEO Sanjeev Luther represented the company in the segment. The presentation recording is available via the Virtual Investor platform.
Cellipont Bioservices and Ernexa Therapeutics (ERNA) announced a manufacturing collaboration on Oct. 29, 2025 to advance ERNA-101, Ernexa's lead allogeneic iMSC cell therapy for ovarian cancer, toward clinical manufacturing and trials. The agreement covers engineering, differentiation, and production (EDP) activities and cGMP development and scale-up of the ERNA-101 process. ERNA-101 has shown preclinical potential to convert immunologically "cold" tumors into "hot" tumors, with data presented at AACR and ASCO. No financial terms or clinical timelines were disclosed.
Cellipont Bioservices and Ernexa Therapeutics (Nasdaq: ERNA) announced a collaboration on Oct 29, 2025 to advance ERNA-101, Ernexa's lead allogeneic iMSC cell therapy for ovarian cancer, into clinical manufacturing and trials. The agreement covers Engineering, Differentiation, and Production (EDP) activities and cGMP development and scale-up of the ERNA-101 manufacturing process.
ERNA-101 is an off-the-shelf iMSC therapy designed to reprogram immunologically "cold" tumors to "hot" ones; preclinical data were presented at AACR and ASCO. The partnership targets translating preclinical promise into a clinically viable therapy.
Ernexa Therapeutics (Nasdaq: ERNA), a company focused on developing cell therapies for cancer and autoimmune diseases, will present at the Cell & Gene Meeting on the Mesa on October 7, 2025 in Phoenix, Arizona.
The company will showcase its pipeline, including ERNA-101, a cell therapy targeting ovarian cancer, and ERNA-201 for autoimmune disease treatment. Both therapies utilize Ernexa's proprietary synthetic, allogeneic induced mesenchymal stem cell (iMSC) technology to create off-the-shelf treatments.
Recently, Ernexa presented new data on ERNA-101 at the AACR Special Conference, demonstrating how their gene-modified iPSC-derived MSC technology improves the immune microenvironment in high-grade serous ovarian cancer.
Ernexa Therapeutics (Nasdaq: ERNA), a cell therapy company, announced that CEO Sanjeev Luther will participate in a panel discussion at the 5th Annual iPSC Drug Development Summit on October 1, 2025, in Boston.
The company is developing engineered induced mesenchymal stem cells (iMSC) therapies, including ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease. Ernexa's approach focuses on creating scalable, allogeneic, off-the-shelf treatments without requiring patient-specific cell harvesting. The company recently presented data on ERNA-101's ability to restore a "hot" immune microenvironment in high-grade serous ovarian cancer at an AACR Special Conference.
FAQ
What is the current stock price of Ernexa (ERNA)?
What is the market cap of Ernexa (ERNA)?
